RATIONALE: Ayahuasca is an Amazonian tea containing the natural psychedelic 5-HT(2A/2C/1A) agonist N,N-dimethyltryptamine (DMT). It is used in ceremonial contexts for its visionary properties. The human pharmacology of ayahuasca has been well characterized following its administration in single doses. OBJECTIVES: To evaluate the human pharmacology of ayahuasca in repeated doses and assess the potential occurrence of acute tolerance or sensitization. METHODS: In a double-blind, crossover, placebo-controlled clinical trial, nine experienced psychedelic drug users received PO the two following treatment combinations at least 1 week apart: (a) a lactose placebo and then, 4 h later, an ayahuasca dose; and (b) two ayahuasca doses 4 h apart. All ayahuasca doses were freeze-dried Amazonian-sourced tea encapsulated to a standardized 0.75 mg DMT/kg bodyweight. Subjective, neurophysiological, cardiovascular, autonomic, neuroendocrine, and cell immunity measures were obtained before and at regular time intervals until 12 h after first dose administration. RESULTS:DMT plasma concentrations, scores in subjective and neurophysiological variables, and serum prolactin and cortisol were significantly higher after two consecutive doses. When effects were standardized by plasma DMT concentrations, no differences were observed for subjective, neurophysiological, autonomic, or immunological effects. However, we observed a trend to reduced systolic blood pressure and heart rate, and a significant decrease for growth hormone (GH) after the second ayahuasca dose. CONCLUSIONS: Whereas there was no clear-cut tolerance or sensitization in the psychological sphere or most physiological variables, a trend to lower cardiovascular activation was observed, together with significant tolerance to GH secretion.
RCT Entities:
RATIONALE: Ayahuasca is an Amazonian tea containing the natural psychedelic 5-HT(2A/2C/1A) agonist N,N-dimethyltryptamine (DMT). It is used in ceremonial contexts for its visionary properties. The human pharmacology of ayahuasca has been well characterized following its administration in single doses. OBJECTIVES: To evaluate the human pharmacology of ayahuasca in repeated doses and assess the potential occurrence of acute tolerance or sensitization. METHODS: In a double-blind, crossover, placebo-controlled clinical trial, nine experienced psychedelic drug users received PO the two following treatment combinations at least 1 week apart: (a) a lactose placebo and then, 4 h later, an ayahuasca dose; and (b) two ayahuasca doses 4 h apart. All ayahuasca doses were freeze-dried Amazonian-sourced tea encapsulated to a standardized 0.75 mg DMT/kg bodyweight. Subjective, neurophysiological, cardiovascular, autonomic, neuroendocrine, and cell immunity measures were obtained before and at regular time intervals until 12 h after first dose administration. RESULTS:DMT plasma concentrations, scores in subjective and neurophysiological variables, and serum prolactin and cortisol were significantly higher after two consecutive doses. When effects were standardized by plasma DMT concentrations, no differences were observed for subjective, neurophysiological, autonomic, or immunological effects. However, we observed a trend to reduced systolic blood pressure and heart rate, and a significant decrease for growth hormone (GH) after the second ayahuasca dose. CONCLUSIONS: Whereas there was no clear-cut tolerance or sensitization in the psychological sphere or most physiological variables, a trend to lower cardiovascular activation was observed, together with significant tolerance to GH secretion.
Authors: J Riba; A Rodríguez-Fornells; G Urbano; A Morte; R Antonijoan; M Montero; J C Callaway; M J Barbanoj Journal: Psychopharmacology (Berl) Date: 2001-02 Impact factor: 4.530
Authors: Anthony G Romano; Jennifer L Quinn; Luchuan Li; Kuldip D Dave; Emmanuelle A Schindler; Vincent J Aloyo; John A Harvey Journal: Psychopharmacology (Berl) Date: 2010-09-09 Impact factor: 4.530
Authors: José Carlos Bouso; Josep Maria Fábregas; Rosa Maria Antonijoan; Antoni Rodríguez-Fornells; Jordi Riba Journal: Psychopharmacology (Berl) Date: 2013-06-21 Impact factor: 4.530
Authors: Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak Journal: Ther Adv Psychopharmacol Date: 2016-03-18
Authors: Eduardo Ekman Schenberg; João Felipe Morel Alexandre; Renato Filev; Andre Mascioli Cravo; João Ricardo Sato; Suresh D Muthukumaraswamy; Maurício Yonamine; Marian Waguespack; Izabela Lomnicka; Steven A Barker; Dartiu Xavier da Silveira Journal: PLoS One Date: 2015-09-30 Impact factor: 3.240
Authors: Fernanda Palhano-Fontes; Katia C Andrade; Luis F Tofoli; Antonio C Santos; Jose Alexandre S Crippa; Jaime E C Hallak; Sidarta Ribeiro; Draulio B de Araujo Journal: PLoS One Date: 2015-02-18 Impact factor: 3.240
Authors: José Carlos Bouso; Débora González; Sabela Fondevila; Marta Cutchet; Xavier Fernández; Paulo César Ribeiro Barbosa; Miguel Ángel Alcázar-Córcoles; Wladimyr Sena Araújo; Manel J Barbanoj; Josep Maria Fábregas; Jordi Riba Journal: PLoS One Date: 2012-08-08 Impact factor: 3.240